The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Nanobody-Based Cancer Therapy of Solid Tumors
Open accessAbstract
The development of tumor-targeted therapies using monoclonal antibodies has been successful during the last 30 years. Nevertheless, the efficacy of antibody-based therapy is still limited and further improvements are eagerly awaited. One of the promising novel developments that may overcome the drawbacks of monoclonal antibody-based therapies is the employment of nanobodies. Current nanobody-based therapeutics can be divided into three different platforms with nanobodies functioning as: receptor antagonists; targeting moieties of effector domains; or targeting molecules on the surface of nanoparticles. In this article, we describe factors that affect their performance at three different stages: their systemic circulation upon intravenous injection; their extravasation and tumor penetration; and, finally, their interaction with target molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Naturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122
The growing applications of click chemistry
Moses, J. E., & Moorhouse, A. D. (2007) · Chem. Soc. Rev. · doi:10.1039/b613014n · Cited by 2,367
Nanobodies: natural single-domain antibodies
Muyldermans, S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-063011-092449 · Cited by 2,304
Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product
Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M.-L., Kmiecik, T. E., Vande Woude, G. F., & Aaronson, S. A. (1991) · Science · doi:10.1126/science.1846706 · Cited by 2,236
Longmire, M., Choyke, P. L., & Kobayashi, H. (2008) · Nanomedicine · doi:10.2217/17435889.3.5.703 · Cited by 2,149
Targeting MET in cancer: rationale and progress
Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3205 · Cited by 1,423
Holmes, K., Roberts, O. L., Thomas, A. M., & Cross, M. J. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.05.013 · Cited by 1,020
Anatomy of the antibody molecule
Padlan, E. A. (1994) · Molecular Immunology · doi:10.1016/0161-5890(94)90001-9 · Cited by 896
A general protocol for the generation of Nanobodies for structural biology
Pardon, E., Laeremans, T., Triest, S., Rasmussen, S. G. F., Wohlkönig, A., Ruf, A., Muyldermans, S., Hol, W. G. J., Kobilka, B. K., & Steyaert, J. (2014) · Nature Protocols · doi:10.1038/nprot.2014.039 · Cited by 790
Single‐domain antibody fragments with high conformational stability
Dumoulin, M., Conrath, K., Van Meirhaeghe, A., Meersman, F., Heremans, K., Frenken, L. G. J., Muyldermans, S., Wyns, L., & Matagne, A. (2002) · Protein Science · doi:10.1110/ps.34602 · Cited by 638
β-arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7
Rajagopal, S., Kim, J., Ahn, S., Craig, S., Lam, C. M., Gerard, N. P., Gerard, C., & Lefkowitz, R. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912852107 · Cited by 600
Vincke, C., Loris, R., Saerens, D., Martinez-Rodriguez, S., Muyldermans, S., & Conrath, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806889200 · Cited by 572
Sortase-Mediated Protein Ligation: A New Method for Protein Engineering
Mao, H., Hart, S. A., Schink, A., & Pollok, B. A. (2004) · Journal of the American Chemical Society · doi:10.1021/ja039915e · Cited by 534
Miao, Z., Luker, K. E., Summers, B. C., Berahovich, R., Bhojani, M. S., Rehemtulla, A., Kleer, C. G., Essner, J. J., Nasevicius, A., Luker, G. D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610444104 · Cited by 533
Camelid immunoglobulins and nanobody technology
Muyldermans, S., Baral, T. N., Retamozzo, V. C., De Baetselier, P., De Genst, E., Kinne, J., Leonhardt, H., Magez, S., Nguyen, V. K., Revets, H., et al. (2009) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2008.10.299 · Cited by 533
Muyldermans, S., Atarhouch, T., Saldanha, J., Barbosa, J. A. R. G., & Hamers, R. (1994) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/7.9.1129 · Cited by 494
van der Linden, R. H. J., Frenken, L. G. J., de Geus, B., Harmsen, M. M., Ruuls, R. C., Stok, W., de Ron, L., Wilson, S., Davis, P., & Verrips, C. T. (1999) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(99)00030-8 · Cited by 471
Ligand-targeted liposomal anticancer drugs
Sapra, P., & Allen, T. M. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00032-8 · Cited by 438
Potent antibody drug conjugates for cancer therapy
Senter, P. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.023 · Cited by 401
Mamot, C., Drummond, D. C., Noble, C. O., Kallab, V., Guo, Z., Hong, K., Kirpotin, D. B., & Park, J. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1093 · Cited by 382
Efficient Cancer Therapy with a Nanobody-Based Conjugate
Cortez-Retamozo, V., Backmann, N., Senter, P. D., Wernery, U., De Baetselier, P., Muyldermans, S., & Revets, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3935 · Cited by 382
Van de Broek, B., Devoogdt, N., D’Hollander, A., Gijs, H.-L., Jans, K., Lagae, L., Muyldermans, S., Maes, G., & Borghs, G. (2011) · ACS Nano · doi:10.1021/nn1023363 · Cited by 374
Odyssey of a cancer nanoparticle: From injection site to site of action
Nichols, J. W., & Bae, Y. H. (2012) · Nano Today · doi:10.1016/j.nantod.2012.10.010 · Cited by 364
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.
Fujimori, K., Covell, D. G., Fletcher, J. E., & Weinstein, J. N. (1990) · PubMed · Cited by 356
Therapeutic antibody fragments with prolonged in vivo half-lives
Chapman, A. P., Antoniw, P., Spitali, M., West, S., Stephens, S., & King, D. J. (1999) · Nature Biotechnology · doi:10.1038/11717 · Cited by 350
Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies
Roovers, R. C., Laeremans, T., Huang, L., De Taeye, S., Verkleij, A. J., Revets, H., de Haard, H. J., & van Bergen en Henegouwen, P. M. P. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0180-4 · Cited by 346
Self-citationPreclinical screening of anti‐HER2 nanobodies for molecular imaging of breast cancer
Vaneycken, I., Devoogdt, N., Van Gassen, N., Vincke, C., Xavier, C., Wernery, U., Muyldermans, S., Lahoutte, T., & Caveliers, V. (2011) · The FASEB Journal · doi:10.1096/fj.10-180331 · Cited by 315
Tijink, B. M., Laeremans, T., Budde, M., Walsum, M. S.-V., Dreier, T., de Haard, H. J., Leemans, C. R., & van Dongen, G. A. M. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2384 · Cited by 305
In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
Gabizón, A., Horowitz, A. T., Goren, D., Tzemach, D., Shmeeda, H., & Zalipsky, S. (2003) · PubMed · Cited by 295
(2004) · The Women's Oncology Review · doi:10.3109/14733400410001727592 · Cited by 288
A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth
Roovers, R. C., Vosjan, M. J. W. D., Laeremans, T., el Khoulati, R., de Bruin, R. C. G., Ferguson, K. M., Verkleij, A. J., van Dongen, G. A. M. S., & van Bergen en Henegouwen, P. M. P. (2011) · International Journal of Cancer · doi:10.1002/ijc.26145 · Cited by 284
Self-citationCore-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin
Talelli, M., Iman, M., Varkouhi, A. K., Rijcken, C. J. F., Schiffelers, R. M., Etrych, T., Ulbrich, K., van Nostrum, C. F., Lammers, T., Storm, G., et al. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.07.005 · Cited by 267
Efficient tumor targeting by single‐domain antibody fragments of camels
Cortez‐Retamozo, V., Lauwereys, M., Hassanzadeh Gh., G., Gobert, M., Conrath, K., Muyldermans, S., De Baetselier, P., & Revets, H. (2002) · International Journal of Cancer · doi:10.1002/ijc.10212 · Cited by 260
Affinity and Avidity in Antibody-Based Tumor Targeting
Rudnick, S. I., & Adams, G. P. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0627 · Cited by 237
Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody
D'Huyvetter, M., Vincke, C., Xavier, C., Aerts, A., Impens, N., Baatout, S., De Raeve, H., Muyldermans, S., Caveliers, V., Devoogdt, N., et al. (2014) · Theranostics · doi:10.7150/thno.8156 · Cited by 225
Gainkam, L. O. T., Huang, L., Caveliers, V., Keyaerts, M., Hernot, S., Vaneycken, I., Vanhove, C., Revets, H., De Baetselier, P., & Lahoutte, T. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.048538 · Cited by 222
Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor
Li, Y., Wang, J., Wientjes, M. G., & Au, J. L.-S. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.04.006 · Cited by 219
Targeting tumors with nanobodies for cancer imaging and therapy
Oliveira, S., Heukers, R., Sornkom, J., Kok, R. J., & van Bergen en Henegouwen, P. M. P. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.298 · Cited by 206
Self-citationMonoclonal Antibodies in Cancer Therapy: 25 Years of Progress
Oldham, R. K., & Dillman, R. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7438 · Cited by 204
Li, T., Bourgeois, J., Celli, S., Glacial, F., Le Sourd, A., Mecheri, S., Weksler, B., Romero, I., Couraud, P., Rougeon, F., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-201384 · Cited by 202
Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF
Prat, M., Crepaldi, T., Pennacchietti, S., Bussolino, F., & Comoglio, P. M. (1998) · Journal of Cell Science · doi:10.1242/jcs.111.2.237 · Cited by 194
Oliveira, S., van Dongen, G. A. M. S., Walsum, M. S.-V., Roovers, R. C., Stam, J. C., Mali, W., van Diest, P. J., & van Bergen en Henegouwen, P. M. P. (2012) · Molecular Imaging · doi:10.2310/7290.2011.00025 · Cited by 194
Self-citationSPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression
Huang, L., Gainkam, L. O. T., Caveliers, V., Vanhove, C., Keyaerts, M., De Baetselier, P., Bossuyt, A., Revets, H., & Lahoutte, T. (2008) · Molecular Imaging and Biology · doi:10.1007/s11307-008-0133-8 · Cited by 192
Massa, S., Xavier, C., De Vos, J., Caveliers, V., Lahoutte, T., Muyldermans, S., & Devoogdt, N. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500111t · Cited by 184
Site‐Specific Protein Labeling via Sortase‐Mediated Transpeptidation
Popp, M. W., Antos, J. M., & Ploegh, H. L. (2009) · Current Protocols in Protein Science · doi:10.1002/0471140864.ps1503s56 · Cited by 161
Spangler, J. B., Neil, J. R., Abramovitch, S., Yarden, Y., White, F. M., Lauffenburger, D. A., & Wittrup, K. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0913476107 · Cited by 161
Downregulation of EGFR by a novel multivalent nanobody-liposome platform
Oliveira, S., Schiffelers, R. M., van der Veeken, J., van der Meel, R., Vongpromek, R., Henegouwen, P. M. P. V. B. E., Storm, G., & Roovers, R. C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.020 · Cited by 161
Self-citationNanobodies as novel agents for disease diagnosis and therapy
Siontorou, C. G. (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s39428 · Cited by 160
Engineered Single-Domain Antibodies with High Protease Resistance and Thermal Stability
Hussack, G., Hirama, T., Ding, W., MacKenzie, R., & Tanha, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028218 · Cited by 160
Nanobodies Targeting the Hepatocyte Growth Factor: Potential New Drugs for Molecular Cancer Therapy
Vosjan, M. J. W. D., Vercammen, J., Kolkman, J. A., van Walsum, M., Revets, H., & van Dongen, G. A. M. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0891 · Cited by 158
Maussang, D., Mujić-Delić, A., Descamps, F. J., Stortelers, C., Vanlandschoot, P., van Walsum, M., Vischer, H. F., Roy, M. V., Vosjan, M. J. W. D., González-Pajuelo, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.498436 · Cited by 148
Gainkam, L. O. T., Caveliers, V., Devoogdt, N., Vanhove, C., Xavier, C., Boerman, O. C., Muyldermans, S., Bossuyt, A. M., & Lahoutte, T. (2010) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.408 · Cited by 148
Intein Applications: From Protein Purification and Labeling to Metabolic Control Methods
Wood, D. W., & Camarero, J. A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.552653 · Cited by 139
Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy
Talelli, M., Oliveira, S., Rijcken, C. J. F., Pieters, E. H. E., Etrych, T., Ulbrich, K., van Nostrum, R., Storm, G., Hennink, W. E., & Lammers, T. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.09.064 · Cited by 132
Self-citationProft, T. (2009) · Biotechnology Letters · doi:10.1007/s10529-009-0116-0 · Cited by 129
Vaneycken, I., Govaert, J., Vincke, C., Caveliers, V., Lahoutte, T., BAETSELIER, P. D., Raes, G., Bossuyt, A. M., Muyldermans, S., & Devoogdt, N. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069823 · Cited by 128
Differential tumor-targeting abilities of three single-domain antibody formats
Bell, A., Wang, Z. J., Arbabi‐Ghahroudi, M., Chang, T.-T. A., Durocher, Y., Trojahn, U., Baardsnes, J., Jaramillo, M., Li, S., Baral, T. N., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.08.003 · Cited by 126
Baker, J. H. E., Lindquist, K. E., Huxham, L. A., Kyle, A. H., Sy, J., & Minchinton, A. I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4465 · Cited by 125
Altıntaş, I., Heukers, R., van der Meel, R., Lacombe, M., Amidi, M., Henegouwen, P. M. P. V. B. E., Hennink, W. E., Schiffelers, R. M., & Kok, R. J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.11.007 · Cited by 121
Delivery of Cancer Therapeutics Using Nanotechnology
Lim, E., Jang, E., Lee, K., Haam, S., & Huh, Y. (2013) · Pharmaceutics · doi:10.3390/pharmaceutics5020294 · Cited by 121
Behdani, M., Zeinali, S., Khanahmad, H., Karimipour, M., Asadzadeh, N., Azadmanesh, K., Khabiri, A., Schoonooghe, S., Habibi‐Anbouhi, M., Hassanzadeh‐Ghassabeh, G., et al. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.11.013 · Cited by 118
Talelli, M., Rijcken, C. J. F., Oliveira, S., van der Meel, R., Henegouwen, P. M. P. V. B. E., Lammers, T., van Nostrum, C. F., Storm, G., & Hennink, W. E. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.01.015 · Cited by 114
Self-citationNanobody–photosensitizer conjugates for targeted photodynamic therapy
Heukers, R., Henegouwen, P. M. P. V. B. E., & Oliveira, S. (2014) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.12.007 · Cited by 111
Self-citationvan der Meel, R., Oliveira, S., Altıntaş, I., Haselberg, R., van der Veeken, J., Roovers, R. C., Henegouwen, P. M. P. V. B. E., Storm, G., Hennink, W. E., Schiffelers, R. M., et al. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.027 · Cited by 105
Self-citationTherapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects
van de Water, J. A. J. M., Onder, T. B., Agarwal, A. S., Wakimoto, H., Roovers, R. C., Zhu, Y., Kasmieh, R., Bhere, D., Henegouwen, P. M. P. V. B. E., & Shah, K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202832109 · Cited by 95
Behdani, M., Zeinali, S., Karimipour, M., Khanahmad, H., Schoonooghe, S., Aslemarz, A., Seyed, N., Moazzami, R., Baniahmad, F., Habibi‐Anbouhi, M., et al. (2012) · New Biotechnology · doi:10.1016/j.nbt.2012.09.002 · Cited by 89
Heukers, R., Altıntaş, I., Raghoenath, S., Zan, E. D., Pepermans, R. A., Roovers, R. C., Haselberg, R., Hennink, W. E., Schiffelers, R. M., Kok, R. J., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.001 · Cited by 83
Mamot, C., Ritschard, R., Küng, W., Park, J. W., Herrmann, R., & Rochlitz, C. F. (2006) · Journal of drug targeting · doi:10.1080/10611860600691049 · Cited by 74
Kobayashi, H., Le, N., Kim, I. S., Kim, M. K., Pie, J.-E., Drumm, D., Paik, D. S., Waldmann, T. A., Paik, C. H., & Carrasquillo, J. A. (1999) · PubMed · Cited by 73
Defize, L. H. K., Moolenaar, W. H., van der Saag, P. T., & de Laat, S. W. (1986) · The EMBO Journal · doi:10.1002/j.1460-2075.1986.tb04345.x · Cited by 71
Sadeqzadeh, E., Rahbarizadeh, F., Ahmadvand, D., Rasaee, M. J., Parhamifar, L., & Moghimi, S. M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.06.022 · Cited by 67
Fluorescent Affibody Peptide Penetration in Glioma Margin Is Superior to Full Antibody
Sexton, K. J., Tichauer, K. M., Samkoe, K. S., Gunn, J. R., Hoopes, P. J., & Pogue, B. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060390 · Cited by 66
Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice
Newkirk, M. M., Novick, J., Stevenson, M. M., Fournier, M.-J., & Apostolakos, P. (1996) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1996.d01-847.x · Cited by 66
EGFR endocytosis requires its kinase activity and N-terminal transmembrane dimerization motif
Heukers, R., Vermeulen, J. F., Fereidouni, F., Bader, A. N., Voortman, J., Roovers, R. C., Gerritsen, H. C., & Henegouwen, P. M. P. V. B. E. (2013) · Journal of Cell Science · doi:10.1242/jcs.128611 · Cited by 63
Neutralizing Nanobodies Targeting Diverse Chemokines Effectively Inhibit Chemokine Function
Blanchetot, C., Verzijl, D., Mujić-Delić, A., Bosch, L., Rem, L., Leurs, R., Verrips, C. T., Saunders, M. J., de Haard, H., & Smit, M. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.467969 · Cited by 54
Hepatology Principles and Practice
Taylor-Robinson, S. D. (2003) · Gut · doi:10.1136/gut.52.7.1074 · Cited by 49
Bannas, P., Well, L., Lenz, A., Rissiek, B., Haag, F., Schmid, J., Hochgräfe, K., Trepel, M., Adam, G., Ittrich, H., et al. (2014) · Contrast Media & Molecular Imaging · doi:10.1002/cmmi.1548 · Cited by 49
Anti‐c‐ MET Nanobody® – a new potential drug in multiple myeloma treatment
Slørdahl, T. S., Denayer, T., Moen, S. H., Standal, T., Børset, M., Ververken, C., & Rø, T. B. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12185 · Cited by 48
Koh, W., Steffensen, S., González-Pajuelo, M., Hoorelbeke, B., Gorlani, A., Szynol, A., Quigley, A. F., Aasa-Chapman, M. M. I., de Haard, H., Verrips, T. C., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.116699 · Cited by 46
Efficient growth inhibition of EGFR over-expressing tumor cells by an anti-EGFR nanobody
Omidfar, K., Zanjani, F. S. A., Hagh, A. G., Azizi, M. D., Rasouli, S. J., & Kashanian, S. (2013) · Molecular Biology Reports · doi:10.1007/s11033-013-2790-1 · Cited by 45
Araste, F., Ebrahimizadeh, W., Rasooli, I., Rajabibazl, M., & Gargari, S. L. M. (2013) · Biotechnology Letters · doi:10.1007/s10529-013-1340-1 · Cited by 38
van der Meel, R., Oliveira, S., Altıntaş, I., Heukers, R., Pieters, E. H. E., Henegouwen, P. M. P. V. B. E., Storm, G., Hennink, W. E., Kok, R. J., & Schiffelers, R. M. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400212v · Cited by 38
Self-citationHepatology, Principles and Practice: History, Morphology, Biochemistry, Diagnostics, Clinic, Therapy
Kuntz, E., & Kuntz, H.-D. (2001) · Springer eBooks · doi:10.1007/3-540-28977-1 · Cited by 36
Cited by
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
“Antitumor nanobodies can be categorized into three types: naked monomeric or multimeric nanobodies, nanobodies genetically fused to effector domains, and as targeting moieties on liposomes or nanoparticles encapsulating a drug (10, 14).”
BackgroundNanobodies as therapeutics: big opportunities for small antibodies
Steeland, S., Vandenbroucke, R. E., & Libert, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.003 · Cited by 468
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Ultrasmall inorganic nanoparticles: State-of-the-art and perspectives for biomedical applications
Zarschler, K., Rocks, L., Licciardello, N., Boselli, L., Polo, E., Garcia, K. P., De Cola, L., Stephan, H., & Dawson, K. A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.02.019 · Cited by 303
Metadata
- Authors
- Kijanka, M., Dorresteijn, B., Oliveira, S., & van Bergen en Henegouwen, P. M.
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2015-01
- Volume
- 10
- Issue
- 1
- Pages
- 161-174
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W1967851963
- Cited by
- 265
- References
- 87
- FWCI
- 17.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.